According to the ASX website, the top-performing stocks in this index on Tuesday were Yancoal Australia Limited and AUB Group Limited, up 3.35% and 3.00% respectively. Over the last five days, the index has gained 0.50% and 5.15% year to date.As of Tuesday at 4:50 pm (local time), the major ASX indices recorded modest gains. The S&P/ASX 20 rose from 4651.70 to 4668.10, finishing 0.4% higher. The S&P/ASX 50 also edged up, moving from 8164.30 to 8183.40, an increase of 0.2%. Similar progress was seen in the ...

整理 | GLP1减重宝典内容团队 当国际巨头在短短数年内把减肥药变成"千亿美金"赛道，中国市场却仍处于起步阶段——渗透率不到1%。在诺和诺德和礼来两大外资 寡头加速推进多靶点与口服剂型的同时，国内一批企业凭借差异化策略发起追赶。全球研发进入"下半场"，技术迭代、成本和政策将决 定下一轮胜负。 ▍双寡头的实力与节奏：销售、临床、口服化三条战线同时推进 按国际研究机构估算，全球GLP-1/减肥药市场在未来数年仍将保持高速增长，且口服剂型与适应症扩展（如MAFLD、OSA等）会进一 步放大市场规模。与此同时，中国庞大的超重/肥胖人口代表着巨大的未被满足需求：现阶段中国肥胖/减重药物的处方渗透率远低于美 国（美国肥胖人群用药率已接近两位数），中国市场仍处于"从0到1"的放量窗口期。多家机构与咨询报告预计，中国GLP-1市场在2030 年前后将迎来数十亿至数百亿人民币规模的增长。 诺和诺德与礼来已经把GLP-1从糖尿病药拓展为肥胖管理的核心工具。2025年前三季度，诺和诺德司美格鲁肽组合实现了数十亿美元级 别的销售，成为公司收入主力；礼来凭借替尔泊肽实现了更高增速，季度及累计业绩显著上扬。两家的临床与商业节奏互为推动 ...

Core Viewpoint - Belite Bio, Inc has announced a public offering of 2,272,727 American Depositary Shares (ADSs) at a price of $154.00 per ADS, aiming to raise approximately $350 million for commercialization and pipeline development [1][2]. Group 1: Offering Details - The public offering consists of 2,272,727 ADSs priced at $154.00 each, with an additional option for underwriters to purchase up to 340,909 more ADSs [1]. - The expected gross proceeds from the offering are approximately $350 million before deducting underwriting discounts and commissions [1]. - The closing of the offering is anticipated to occur around December 3, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for commercialization preparation, including building an in-house commercialization team and establishing sales networks [2]. - Funds will also be used for the development and expansion of the company's drug pipeline [2]. - Additional proceeds will support working capital and other general corporate purposes [2]. Group 3: Company Overview - Belite Bio is focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration [6]. - The company's lead candidate, Tinlarebant, is an oral therapy aimed at reducing bisretinoid toxins in the eye and has completed a Phase 3 trial in adolescent STGD1 subjects [6].

TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Etalanetug is designed to bind to the microtubule- binding region (MTBR) of tau protein and prevent the seeding and propagation of tau pathology. Anti-tau therapeutic antibody, etalanetug, reduces the novel biomarker plasma eMTBR-tau243 in patien ...

Core Viewpoint - The Trump administration is supporting Bayer's request to the U.S. Supreme Court to limit the number of lawsuits alleging that its Roundup weedkiller causes cancer [1] Group 1 - Bayer is facing thousands of lawsuits related to its Roundup product, which claims it causes cancer [1] - The administration's backing may influence the Supreme Court's decision on whether to hear Bayer's case [1] - The outcome of this legal battle could have significant implications for Bayer's financial liabilities and reputation in the agricultural sector [1]

"In biotech securities cases, the core issue is often whether the company was accurately representing its data and trial design," said Reed Kathrein, the Hagens Berman partner leading the litigation. "The suit alleges that aTyr concealed material adverse facts concerning Efzofitimod's capability to allow a patient to completely taper their steroid usage—a key measure of efficacy—while emphasizing a multi-billion- dollar market. We are scrutinizing whether these prior statements about the drug's prospects cr ...

Chinese vaccine makers are caught in a steep downturn, as intensifying competition pushes prices lower and erodes profits, underscoring the far-reaching deflationary pressure across the world’s second-largest economy https://t.co/gHU1UhbK1g ...

Pelthos Pharmaceuticals ( PTHS ) is a commercial-stage company with a recently launched lead drug, Zelsuvmi. Zelsuvmi is the first at home FDA approved drug for the treatment for molluscum contagiosum. It was approved by the FDA inI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. My ambition here is to cover stocks with consid ...

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out o ...

Key TakeawaysU.S. Treasury Secretary Bessent announced a federal investigation into allegations that Minnesota tax dollars may have been diverted to the terrorist organization Al-Shabaab.Shanghai Bao Pharmaceuticals has launched a global offering of 37.9 million H-shares, signaling a significant move for the biotech firm on the Hong Kong Stock Exchange.Apple (AAPL) is set for a major leadership transition in its Artificial Intelligence division, with AI Chief John Giannandrea retiring in Spring 2026 and a n ...